1. Home
  2. TTRX vs SCII Comparison

TTRX vs SCII Comparison

Compare TTRX & SCII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$9.74

Market Cap

281.2M

Sector

Health Care

ML Signal

HOLD

SCII

SC II Acquisition Corp. Class A ordinary share

N/A

Current Price

$10.11

Market Cap

251.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TTRX
SCII
Founded
2015
2025
Country
United States
United States
Employees
2
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
281.2M
251.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TTRX
SCII
Price
$9.74
$10.11
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$8.00
N/A
AVG Volume (30 Days)
124.1K
34.7K
Earning Date
05-31-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$9.93
52 Week High
$11.69
$10.11

Technical Indicators

Market Signals
Indicator
TTRX
SCII
Relative Strength Index (RSI) N/A 62.29
Support Level N/A $9.96
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.02
MACD 0.00 0.00
Stochastic Oscillator 0.00 100.00

Price Performance

Historical Comparison
TTRX
SCII

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

About SCII SC II Acquisition Corp. Class A ordinary share

SC II Acquisition Corp is a blank check company. The company was incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: